Evoke Pharma Inc's ROI from its third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Evoke Pharma Inc's ROI in the third quarter of 2025?
Evoke Pharma Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter of 2025, resulting in a negative return on investment (ROI) of -101.4%.

Within the Healthcare sector 561 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2025 quarter, so far to 2998, from total ROI ranking in the second quarter of 2025 at 3499.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Investment Change TTM	158.68 %	135.35 %	48.42 %	-3.86 %	-74.35 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	3	4	6	7	4
Return On Investment (TTM)	-101.4 %	-99.48 %	-101.92 %	-121.73 %	-308.51 %
EVOK's Overall Ranking	# 2998	# 3499	# 3026	# 2993	# 3523
Seq. Investment Change TTM	-4.74 %	8.58 %	13.33 %	120.68 %	-13.33 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-5	-5	-5	-5	-6

EVOK Company Profile >> Back to EVOK Roi Comparisons >> See Annual EVOK Return On Investment

Return On Investment EVOK's Ranking
Within:	No.
Industry	# 262
Sector	# 562
Overall	# 2998

Return On Investment Statistics
High	Average	Low
-76.89 %	-182.42 %	-800.17 %
(Mar 31 2023)		(Dec 31 2020)

News about Evoke Pharma Inc Return on Investment ROI

Evoke Pharma: Seizing Opportunities to Revolutionize GI Therapeutics with Recent Underwritten Public Offering

February 9, 2024

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company specializing in gastrointestinal (GI) disease treatments, has recently disclosed the pricing details of its underwritten public offering. The company aims to raise gross proceeds of up to $30 million through this offering, with an initial upfront funding of approximately $7.5 million. The offering is being led by Nantahala Capital Management, along with the participation of other fundamental investors. This substantial funding will further support Evoke Pharma s development and commercialization plans for its key product, GIMOTI (metoclopramide) nasal spray.
GIMOTI nasal spray is a novel therapeutic solution for the treatment of various GI diseases. It is specifically designed to address gastroparesis symptoms in adult women, including nausea and vomiting. By offering a non-oral alternative, GIMOTI has the potential to revolutionize the treatment landscape for patients suffering from this debilitating condition. Evoke Pharma s focused approach in the GI space positions them as a key player in addressing unmet medical needs and providing effective solutions.

Financial Statements
Evoke Pharma Inc's III. Quarter Investments	$ 3 Millions	EVOK's Balance sheet
Evoke Pharma Inc's III. Quarter Income	$ -1 Millions	Quarterly EVOK's Income Statement
EVOK's Income by Division		See EVOK's Income by Division

EVOK Annual Return On Investment	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021	(Dec 31 2020) 2020
Total Investments in Millions	7	-3	10	9	2
Y / Y Investment Growth	-	-	11.23 %	382.91 %	-56.66 %
Net Income in Millions	-5	-8	-8	-9	-13
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-76.05 %	-	-80.65 %	-93.13 %	-692.95 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
EVOK's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for EVOK's Competitors
Subscribers only: Roi for Evoke Pharma Inc's Suppliers
Subscribers only: Return On Investment for EVOK's Customers

Other Ratios
EVOK's Roa	EVOK's Inventory Turnover Ratio	EVOK's Growth Rates	EVOK's Dividend Statistics
	EVOK's Profitability Ratios	EVOK's Asset Turnover Ratio	EVOK's Dividend Growth
EVOK's Roe	EVOK's Valuation Ratios	EVOK's Financial Strength Ratios	EVOK's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2025, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:01:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.